In addition, recent studies suggested that SGLT2 inhibitors had more favorable pleiotropic effects on HbA1c level, body weight, and systolic blood pressures when compared with DPP4 inhibitors, which may result in further arterial dilation and improved atrial remodeling and, thus, reduce the occurrence of AF (Schotten et al., 2011; Kim et al., 2019). Here, DPP4 is linked to atrial fibrillation.